logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Commentary

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...
Journal Article
|
Letter

Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen

Achar J, Berry C, Herboczek K, Parpieva N, Tillashaykhov M,  et al.
2015-09-09 • Emerging Infectious Diseases
2015-09-09 • Emerging Infectious Diseases
Journal Article
|
Research

Challenges and solutions to implementing drug-resistant tuberculosis programmes for children in Central Asia

du Cros PAK, Swaminathan A, Bobokhojaev O, Sharifovna ZD, Martin C,  et al.
2015-06-21 • Public Health Action
2015-06-21 • Public Health Action
Guidelines for children with drug-resistant tuberculosis (DR-TB) tend to focus on individual patient care; there is little guidance for national tuberculosis programmes (NTPs) on how to...
Journal Article
|
Research

Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis

Achar J, Hewison CCH, Cavalheiro AP, Skrahina A, Cajazeiro J,  et al.
2017-10-01 • Emerging Infectious Diseases
2017-10-01 • Emerging Infectious Diseases
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessati...
Journal Article
|
Research

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

du Cros PAK, Khamraev AK, Tigay Z, Abdrasuliev T, Greig J,  et al.
2021-02-08 • ERJ open research
2021-02-08 • ERJ open research
BACKGROUND
In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9–12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment....